Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

More money comes in to further work on gene therapy for choroideremia

NightstaRx Ltd (Nightstar), a biopharmaceutical company spun out from the University of Oxford specialising in developing gene therapies for inherited retinal dystrophies, has announced that it has completed a $35 million  (£23.2 million) funding round. The round was led by New Enterprise Associates (NEA), one of the world’s leading venture capital firms. 

Nightstar’s lead programme is a gene therapy for an inherited form of progressive blindness, choroideremia, developed by Professor Robert MacLaren at Oxford’s Nuffield Laboratory of Ophthalmology, part of the Nuffield Department of Clinical Neurosciences. 

Read more...

Similar stories

NICE recommends offering app-based treatment for people with insomnia instead of sleeping pills

Hundreds of thousands of people suffering from insomnia who would usually be prescribed sleeping pills could be offered an app-based treatment programme instead, NICE has said.

How to use the science of the body clock to improve our sleep and health

Professor Russell Foster has written a new book about circadian neuroscience which is published by Penguin this week. This book review by Jacqueline Pumphrey was first published on the University of Oxford website.

Obituary: Carol Holder

Major research network to investigate body clock and stroke

The University of Oxford is part of a new international research network to investigate the interactions between the biology of the body's internal clock and the disordered physiological processes associated with stroke.

New genetic diagnosis technology for eye disease receives major funding award

Eye2Gene explores the use of AI to determine which genetic condition is causing a patient’s inherited retinal disease, by examining eye scans.

How our dreams changed during the COVID-19 pandemic

This study explored associations between COVID-19 and dream recall frequency, and related social, health, and mental health factors.